Relapse Refractory Acute Myeloid Leukemia
Showing 1 - 25 of >10,000
Refractory/Relapse Acute Myeloid Leukemia Trial in Kunming (Venetoclax)
Recruiting
- Refractory/Relapse Acute Myeloid Leukemia
-
Kunming, Yunnan, ChinaDepartment of Hematology,920th Hospital of Joint Logistic Suppor
Mar 28, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted
Recruiting
- Acute Myeloid Leukemia
- +3 more
- CD123 targeted CAR-NK cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Aug 28, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma Trial in Winston-Salem (drug,
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- +2 more
- CPI 613
- +3 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
May 10, 2023
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse Trial in Miami (Bomedemstat,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Miami, FloridaUniversity of Miami
Dec 22, 2022
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States
Recruiting
- Refractory Acute Myeloid Leukemia
- +4 more
- CD371-YSNVZ-IL18 CAR T cells
-
Basking Ridge, New Jersey
- +6 more
Aug 29, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti-siglec-6 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti-siglec-6 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Aug 2, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Edegem, Roeselare (Venetoclax, 6-mercaptopurine)
Recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
-
Edegem, Antwerp, Belgium
- +1 more
Aug 16, 2022
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,
Recruiting
- Stem Cell Transplant Complications
- +4 more
- Radiation
- +7 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 19, 2023
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Seattle (SC-DARIC33)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- SC-DARIC33
-
Seattle, WashingtonSeattle Children's Hospital
Sep 6, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia Trial in
Recruiting
- Acute Myeloid Leukemia Refractory
- +2 more
-
Houston, Texas
- +4 more
Jun 23, 2022
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation Trial (Ziftomenib, Venetoclax,
Not yet recruiting
- Acute Myeloid Leukemia
- +10 more
- Ziftomenib
- +4 more
- (no location specified)
Feb 17, 2023
Acute Myeloid Leukemia, in Relapse Trial in Baltimore, Chapel Hill (pembrolizumab,)
Active, not recruiting
- Acute Myeloid Leukemia, in Relapse
-
Baltimore, Maryland
- +1 more
Aug 10, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Boston (Iadademstat, Gilteritinib Oral Tablet)
Recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Iadademstat
- Gilteritinib Oral Tablet
-
Boston, Massachusetts
- +2 more
Jan 18, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Trial in Zhengzhou (6MW3211
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- +2 more
- 6MW3211 injection with Intravenous Infusion
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jul 2, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (BP1002; Liposomal Bcl-2 Antisense
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- Decitabine (in combination with BP1002)
- (no location specified)
Mar 8, 2022
MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)
Recruiting
- Myelodysplastic Syndromes, de Novo
- +10 more
- Venetoclax
- +10 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 23, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory Trial in Philadelphia
Recruiting
- Acute Myeloid Leukemia, in Relapse
- +2 more
- CART123 cells; cyclophosphamide; fludarabine
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Feb 28, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (Venetoclax, Azacitadine, Vorinostat)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Venetoclax
- +5 more
- (no location specified)
Apr 11, 2022
Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia Trial in Boston (GO-203-2c, GO-203-2c + Decitabine)
Active, not recruiting
- Acute Myeloid Leukemia, in Relapse
- Recurrent Adult Acute Myeloid Leukemia
- GO-203-2c
- GO-203-2c + Decitabine
-
Boston, Massachusetts
- +1 more
Jan 25, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Cyclophosphamide (Non-IMP, Lymphodepletion)
- +3 more
-
Ulm, Baden-Württemberg, Germany
- +4 more
Jul 24, 2023
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte
Active, not recruiting
- Adult Acute Myeloid Leukemia in Remission
- +12 more
- cyclophosphamide
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
B-Cell Lymphoma, MDS (MDS), Acute Myeloid Leukemia (AML) Trial in Houston (Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells,
Not yet recruiting
- B-Cell Lymphoma
- +2 more
- Cyclophosphamide
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 12, 2022